[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 1,524
Citations 0
In This Issue of JAMA
September 12, 2017

Highlights

JAMA. 2017;318(10):883-885. doi:10.1001/jama.2016.13300

Sentinel lymph node dissection (SLND) is noninferior to axillary lymph node dissection (ALND) in patients with invasive breast cancer followed up for a median of 6.3 years, but there is concern about late recurrence. In a randomized clinical trial, Giuliano and colleagues studied 891 women who had surgery for breast cancer and found that the noninferiority of SLND for the outcome of overall survival persisted for up to 10 years. In an Editorial, Livingston and Li suggest that less than perfect clinical trials may yield evidence to improve patients’ quality of life without increasing their risk of mortality.

First Page Preview View Large
First page PDF preview
First page PDF preview
×